Ballerup, Denmark and Redwood City, CA, USA – July 11, 2022 – Norlase, an emerging global medical device company designing a new generation of ultra-compact ophthalmic lasers, is pleased to announce that Douglas Cheah has joined the company’s growing Global Sales team as Regional Director, Asia Pacific. Based in Kuala Lumpur, Malaysia, Mr. Cheah joins Norlase with over thirty years of experience in the medical device industry. In the last fifteen years, Mr. Cheah expertly managed sales for the Asia Pacific region for ophthalmic laser manufacturer IRIDEX.
“Douglas’ extensive knowledge of Asia Pacific, his well-established relationships in the region, and his deep understanding of its unique needs is matched by his passion, leadership, and outlook for the advancement of ophthalmic laser technologies,” said Oliver Hvidt, Norlase CEO and President. “Our international sales team benefits from his experience and we look forward to the ways in which we can revolutionize care for innumerable healthcare professionals and their patients in APAC.”
Prior to joining Norlase, Mr. Cheah also managed ophthalmic surgical instrument sales in Southeast Asia at Storz Instrument Company prior to its acquisition by Bausch & Lomb, which eventually merged with Chiron to form Bausch & Lomb Surgical. He is a global sales leader and has managed extensive medical device portfolios. He has assisted many doctors with the clinical application of surgical instruments and systems, and brings key insights into product design and development along with strategies for growth and adoption in new markets.
“I truly believe that Norlase’s next-generation medical devices represent the bright future of laser photocoagulation,” said Mr. Cheah. “I’m thrilled to introduce LEAF and LION to the market here in APAC, where our partners are impressed and eager to share with their customers the game-changing technology, superior standards, and innovation that Norlase has established.”
For more information about Norlase, visit www.norlase.com.
About Norlase
Norlase develops next-generation laser solutions for the treatment of retina and glaucoma diseases. Founded in Denmark, Norlase is comprised of worldwide industry experts in ophthalmology, laser technology, medical device development, and customer care. Norlase is on a mission to improve practice efficiency, patient care and physician convenience for ophthalmologists worldwide. Norlase entered the United States ophthalmic market with LEAF, a new laser photocoagulator that’s 10X smaller than existing systems and mounts directly on the slit-lamp.
Ballerup, Denmark and Redwood City, CA, USA – July 11, 2022 – Norlase, an emerging global medical device company designing a new generation of ultra-compact ophthalmic lasers, is pleased to announce that Douglas Cheah has joined the company’s growing Global Sales team as Regional Director, Asia Pacific. Based in Kuala Lumpur, Malaysia, Mr. Cheah joins Norlase with over thirty years of experience in the medical device industry. In the last fifteen years, Mr. Cheah expertly managed sales for the Asia Pacific region for ophthalmic laser manufacturer IRIDEX.
“Douglas’ extensive knowledge of Asia Pacific, his well-established relationships in the region, and his deep understanding of its unique needs is matched by his passion, leadership, and outlook for the advancement of ophthalmic laser technologies,” said Oliver Hvidt, Norlase CEO and President. “Our international sales team benefits from his experience and we look forward to the ways in which we can revolutionize care for innumerable healthcare professionals and their patients in APAC.”
Prior to joining Norlase, Mr. Cheah also managed ophthalmic surgical instrument sales in Southeast Asia at Storz Instrument Company prior to its acquisition by Bausch & Lomb, which eventually merged with Chiron to form Bausch & Lomb Surgical. He is a global sales leader and has managed extensive medical device portfolios. He has assisted many doctors with the clinical application of surgical instruments and systems, and brings key insights into product design and development along with strategies for growth and adoption in new markets.
“I truly believe that Norlase’s next-generation medical devices represent the bright future of laser photocoagulation,” said Mr. Cheah. “I’m thrilled to introduce LEAF and LION to the market here in APAC, where our partners are impressed and eager to share with their customers the game-changing technology, superior standards, and innovation that Norlase has established.”
For more information about Norlase, visit www.norlase.com.
About Norlase
Norlase develops next-generation laser solutions for the treatment of retina and glaucoma diseases. Founded in Denmark, Norlase is comprised of worldwide industry experts in ophthalmology, laser technology, medical device development, and customer care. Norlase is on a mission to improve practice efficiency, patient care and physician convenience for ophthalmologists worldwide. Norlase entered the United States ophthalmic market with LEAF, a new laser photocoagulator that’s 10X smaller than existing systems and mounts directly on the slit-lamp.
DIDN’T FIND WHAT YOU’RE LOOKING FOR?
Let us know how we can help!
DIDN’T FIND WHAT YOU
WERE LOOKING FOR?
Let us know how we can help!
